BMO Capital Maintains Market Perform on Mirati Therapeutics, Lowers Price Target to $31
Portfolio Pulse from richadhand@benzinga.com
BMO Capital analyst Evan David Seigerman has maintained a 'Market Perform' rating on Mirati Therapeutics (NASDAQ:MRTX) but lowered the price target from $40 to $31.
August 09, 2023 | 2:37 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BMO Capital has maintained its 'Market Perform' rating on Mirati Therapeutics but lowered the price target from $40 to $31.
The lowering of the price target by BMO Capital from $40 to $31 indicates a less optimistic outlook for Mirati Therapeutics. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100